← Back to news
S

Seeking Alpha: News

China's factory output hits 14-month low, retail and jobs show slight resilience; fixed-asset investment sees sharpest drop since 2020

B

Secure Waste Infrastructure announces C$300 million private placement

B

Gartner prices $800M senior notes

B

Alstom ADR reports 1H results; reaffirms FY outlook

B

Enthusiast Gaming Holdings GAAP EPS of C$0.04, revenue of C$7.3M

B

Aptose Biosciences GAAP EPS of -$2.01

B

Skeena Resources GAAP EPS of -C$0.32

B

South Bow reports mixed Q3 results; initiates FY26 and updates FY25 outlook

B

PBCO Financial COO to step down

B

Battalion Oil Non-GAAP EPS of -$0.96, revenue of $43.48M

B

Applied Digital prices $2.35 billion senior notes

S

Superior Plus Corp. declares CAD 0.045 dividend

S

CES Energy Solutions declares CAD 0.0425 dividend

S

Weyerhaeuser declares $0.21 dividend

S

Cabot declares $0.45 dividend

S

BitMine Immersion Technologies names Chi Tsang as CEO

S

Faraday Future Intelligent Electric reports Q3 results

S

Ecopetrol reports Q3 results

S

Friday's Economic Calendar

S

Research Solutions targets continued ARR and EBITDA expansion through AI-driven B2B growth

S

GeoVax outlines expedited GEO-MVA clinical trial and global partnership strategy for 2025-2026

S

Vaxart extends cash runway into Q2 2027 with Dynavax partnership and targets 2026 data readouts

S

Quantum outlines $67M Q3 revenue target following debt restructuring and surge in $25M backlog

S

Aterian maintains $36M-$38M H2 revenue guidance while expanding consumables and channels for 2026 growth

S

Evolv projects 20% ARR growth for 2026 as direct model and new products drive outlook

S

Origin Materials outlines $100M-$200M 2027 revenue target as PET cap production and global expansion accelerate

S

Beazer Homes targets over 200 communities by 2027 as margin improvement steps advance

S

TSS expects 50%-75% full-year EBITDA growth while advancing AI integration capabilities

B

Trevi Therapeutics targets multiple phase III trial launches for chronic cough indications in 2026 as regulatory plans accelerate

B

Aytu BioPharma outlines $10M EXXUA launch investment and targets breakeven at $17.3M quarterly revenue as ADHD franchise holds strong

B

Applied Materials projects 2026 growth led by AI-driven foundry logic and DRAM

B

Virgin Galactic outlines 125 spaceflights per year target as company pivots toward 2026 commercial launch

S

Tela Bio outlines at least 16% 2025 revenue growth target while strengthening commercial team and balance sheet

S

Cibus outlines $200M annual rice royalty target while advancing global commercialization strategy

B

GameSquare expects over 20% annual organic revenue growth in 2026 as profitability and digital asset yields accelerate

B

Glimpse Group signals Brightline IPO spin-off and targets Foretell AI as revenue foundation amid Q1 revenue decline

S

Owlet raises 2025 revenue guidance to $103M-$106M while expanding global Dream Sock adoption

B

TMC targets over $400M in potential warrant cash inflow as U.S. pivot accelerates

S

Oil futures bounce after selloff despite 'bearish' build in U.S. crude inventories

S

FitLife Brands signals ongoing margin pressure and consumer softness following Irwin Naturals acquisition

S

Strata Skin Sciences outlines threefold market expansion opportunity as CPT code revisions approach 2027

S

Hyperfine outlines $5M-$6M Q4 revenue target and accelerated growth following next-gen system launch

S

TOI raises 2025 revenue outlook to $495M-$505M as pharmacy growth accelerates and adjusted EBITDA turns positive

S

Daré targets DARE to PLAY launch in December 2025 as dual path strategy accelerates

S

Xos outlines $50.2M–$65.8M 2025 revenue target while expanding higher-margin product lines and Hub platform

S

TriSalus reaffirms 50% revenue growth target while advancing TriNav platform and product launches

S

Fossil reiterates breakeven to slightly positive adjusted operating margin outlook for 2025 following balance sheet transformation

S

Relmada signals 2026 launch of two pivotal studies for NDV-01 and sepranolone, supported by $100M financing

S

Cytosorbents outlines cash flow breakeven targets for Q1 2026 through workforce and cost restructuring

S

Sera Prognostics outlines accelerated Medicaid pilot expansion to 13 states as commercialization momentum builds

S